RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals - Wikidata - wikimedia - TriplyDB

RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals

RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals

http://www.wikidata.org/entity/Q35442056

about

Mechanistic relationship between the vagal afferent pathway, central nervous system and peripheral organs in appetite regulation 60 YEARS OF POMC: Regulation of feeding and energy homeostasis by α-MSH Gut-Brain Cross-Talk in Metabolic Control.Obesity: Current and potential pharmacotherapeutics and targets.Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity.Temporal cAMP Signaling Selectivity by Natural and Synthetic MC4R Agonists.Discovery of Mixed Pharmacology Melanocortin-3 Agonists and Melanocortin-4 Receptor Tetrapeptide Antagonist Compounds (TACOs) Based on the Sequence Ac-Xaa1-Arg-(pI)DPhe-Xaa4-NH2.Melanocortin-4 receptor-regulated energy homeostasis A Life without Hunger: The Ups (and Downs) to Modulating Melanocortin-3 Receptor Signaling.Latest approaches for the treatment of obesity.Design of cyclized selective melanotropins.Ultraviolet radiation, vitamin D and the development of obesity, metabolic syndrome and type-2 diabetes.Role of the brain melanocortins in blood pressure regulation.Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.Biased signaling at neural melanocortin receptors in regulation of energy homeostasis.Magel2-null mice are hyper-responsive to setmelanotide, a melanocortin 4 receptor agonist.Melanocortin-4 Receptor Deficiency Phenotype with an Interstitial 18q Deletion: A Case Report of Severe Childhood Obesity and Tall Stature.Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.Use and Importance of Nonhuman Primates in Metabolic Disease Research: Current State of the Field.The current state of GPCR-based drug discovery to treat metabolic disease.Development of Novel Melanocortin Receptor Agonists Based on the Cyclic Peptide Framework of Sunflower Trypsin Inhibitor-1.Neuroendocrinology: New hormone treatment for obesity caused by POMC-deficiency.Binding, Thermodynamics, and Selectivity of a Non-peptide Antagonist to the Melanocortin-4 Receptor.

P2860

Q26749523-EED9D89C-4E8F-4F14-AB25-33B23552C75E Q26768703-FE943411-1284-4C5D-922E-4D451AEB99A0 Q30235568-5CCB78E7-6DB9-414C-82EC-42BFA7E0CF4F Q30243992-E49DB57C-A7D4-4F8E-8EE8-531712FBF457 Q33830475-037A5AC7-131B-419E-A67C-0EA0525AEE4A Q36232983-B42C8619-AEE6-42FF-8818-3FEAD19D5C41 Q36357786-A83AF48F-E87E-4F8E-896A-DE364318D43A Q37593898-2C64AA85-B9CD-484A-9416-63637364CEE3 Q37703081-91B31806-8558-4048-B2BB-DB6BA67D4F8F Q38475978-20397B0C-8786-40C3-8019-39505EE1062A Q38937114-8D5253D2-C25E-40A9-A3F9-F02E0ACBCE44 Q39051699-0C88D842-FDB8-4563-A9BC-CF87F9073AFE Q39169242-6F35122F-52CD-4192-9837-5462327162A5 Q39211934-2304651C-0FE9-44C6-8954-4FEE791FFD85 Q39256591-5F5D52E4-044B-490C-B90B-0DA70B4BAFA0 Q39658308-51295920-B2A3-47D9-89B7-FECE55FB1BC5 Q41321460-BECAD1E2-73E3-49C3-ADBA-DE72049987F5 Q42377845-36D9D93B-46D0-4EDD-B046-9B5DA3658A76 Q46036092-B26E2433-700F-478D-9131-00311197D580 Q47696468-07FF74B3-B688-4774-8E92-96FB755035CF Q52615555-108CADCF-0A48-4F00-95CF-2D4848D2A2E8 Q53760093-D9921A2A-816E-4BF2-9CF7-8D42DEFAAC42 Q55092101-A11E6A28-680E-43FB-8B20-336EF869CC9F

P2860

RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals

http://www.wikidata.org/entity/Q35442056

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

RM-493, a melanocortin-4 recep ...... penditure in obese individuals

@ast

RM-493, a melanocortin-4 recep ...... penditure in obese individuals

@en

type

label

RM-493, a melanocortin-4 recep ...... penditure in obese individuals

@ast

RM-493, a melanocortin-4 recep ...... penditure in obese individuals

@en

prefLabel

RM-493, a melanocortin-4 recep ...... penditure in obese individuals

@ast

RM-493, a melanocortin-4 recep ...... penditure in obese individuals

@en

P1433

Q35442056-0E24483F-232D-47F4-8828-20DD8F1A4CEB

P1476

Q35442056-53CF0AFC-16DD-476F-8C89-95E4B952CE02

P2093

Q35442056-1C13AB44-13F0-4215-8037-0F25994542EE

Q35442056-272E9921-6D30-4188-BD2A-8E0700C20C88

Q35442056-2B2B3DC6-39B4-4D73-90FE-D1967C80FAB4

Q35442056-3244624C-22D4-4E54-9E44-3E3E7A4B5843

Q35442056-34102155-BB55-43B3-9EED-1E01728C7992

Q35442056-64EDCFCA-08CF-4C1C-B975-53D28AF0B516

Q35442056-8828010F-D1D4-458D-9DF4-AB66E136E561

Q35442056-AEE01865-3ECB-4D70-A1B2-9A47ECA31541

Q35442056-B5626E4F-F5F8-43B6-98CF-0CF105CF0F78

Q35442056-CB3EBFB3-2422-4693-BDAE-4EDD6D265BC5

P2860

Q35442056-1788B4AF-0727-4E79-8A9E-6EDED6659023

Q35442056-1820832E-C59C-4B4A-A7EF-C28E57784BF5

Q35442056-252A4150-18E9-4565-8A5A-64D4019620F7

Q35442056-344E7A6F-4DB6-4E20-B8E2-C64D0E004FD3

Q35442056-3B596D88-A4A9-4C21-BC9B-91685F4F74F6

Q35442056-3EA8EE7C-8B7D-490F-861C-3A184ACA33F0

Q35442056-42427A52-845A-47B0-92DF-000CB35DEA4E

Q35442056-4B5B7133-E6ED-42FF-9DE5-94E9AA21C92E

Q35442056-4C7514F5-3810-414A-91D7-DC438212996D

Q35442056-549620D1-50C7-46C9-BADB-39C7CA3E8254

P304

Q35442056-A2A04197-ACDC-431C-8BBE-E924DBBA91F6

P31

Q35442056-8DDE6304-42E5-4A08-B341-0FC01929BBD3

P356

Q35442056-CF939852-DE43-4113-8A6E-D57266E6010A

P407

Q35442056-53AE5512-1DF5-46AB-9F85-CA23BEF450E5

P433

Q35442056-0F66D6C1-1F4F-4FBF-A909-2423BFA012FA

P478

Q35442056-1886E074-D266-4575-9B7F-165C5484B50A

P50

Q35442056-349C4DF0-67A5-4B76-86EC-03335D25049B

Q35442056-5B0556D9-489D-471A-924D-19241305F7F5

P577

Q35442056-16591B46-4E6F-4DD4-92AC-7D1D03F75687

P698

Q35442056-7738837A-AE87-4E88-B587-4AC59C7EC508

P921

Q35442056-E713C531-88A5-4FF3-910C-0ED32528E496

P932

Q35442056-565D12F4-CD69-4606-9321-62F4F777C28A

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

RM-493, a melanocortin-4 recep ...... penditure in obese individuals

@en

P2093

Brandon L Panaro

http://www.w3.org/2001/XMLSchema#string

Brent S Abel

http://www.w3.org/2001/XMLSchema#string

Katherine P Mullins

http://www.w3.org/2001/XMLSchema#string

Keith M Gottesdiener

http://www.w3.org/2001/XMLSchema#string

Lex H T Van der Ploeg

http://www.w3.org/2001/XMLSchema#string

Michael Ring

http://www.w3.org/2001/XMLSchema#string

Monica C Skarulis

http://www.w3.org/2001/XMLSchema#string

Pamela Staker

http://www.w3.org/2001/XMLSchema#string

Ranganath Muniyappa

http://www.w3.org/2001/XMLSchema#string

Robert J Brychta

http://www.w3.org/2001/XMLSchema#string

P2860

Role of melanocortinergic neurons in feeding and the agouti obesity syndrome

The Central Melanocortin System and Energy Homeostasis.

Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques.

Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat.

Determinants of 24-hour energy expenditure in man. Methods and results using a respiratory chamber

Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study.

Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects

Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity

The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology.

Studies on the physiological functions of the melanocortin system.

P304

1639-1645

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2014-4024

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Marc L. Reitman

P577

2015-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25675384

http://www.w3.org/2001/XMLSchema#string

P921

P932

4399297

http://www.w3.org/2001/XMLSchema#string